Clinical Trials Directory

Trials / Completed

CompletedNCT01907490

Safety and PK Study of Ha44 Gel Under Maximal Use Conditions for Treatment of Head Lice Infestation

A Safety and Pharmacokinetic Study of Ha44 Gel Administered Topically Under Maximal Use Conditions for the Treatment of Head Lice Infestation.

Status
Completed
Phase
Phase 2
Study type
Interventional
Enrollment
38 (actual)
Sponsor
Dr. Reddy's Laboratories Limited · Industry
Sex
All
Age
6 Months – 17 Years
Healthy volunteers
Not accepted

Summary

The purpose of the study is to evaluate the safety and tolerability of a single application of Ha44 Gel 0.74% w/v for the treatment of head lice under maximal use conditions. Secondary objective is to evaluate pharmacokinetics of Ha44 and benzyl alcohol (contained in Ha44 vehicle) under maximal use conditions.

Detailed description

This is an open-label safety and pharmacokinetic (PK) study involving a single application of Ha44 Gel 0.74% administered under maximal use conditions. All participants must have an active head lice infestation (at least 3 live lice) and be 6 months to 17 years of age. The study will enroll approximately 36 pediatric subjects between the ages of 6 months and 17 years. Pediatric PK samples will be collected at 0 (predose), 30 and 60 mins and 2 and 8 hrs time points. More than one household member with an active lice infestation may participate in the study. Eligible subjects will be consented and screened for study eligibility on Day 0 (Visit 1). All subjects will return to the study site for three follow-up clinic visits at Days 1, 7 and 14. The maximum study duration for a subject is 16 days.

Conditions

Interventions

TypeNameDescription
DRUGHa44 GelEligible subjects will be treated at the study site on Day 0 with a single application of the maximum feasible amount of Ha44 Gel, to ensure saturation of the scalp and hair.

Timeline

Start date
2013-03-01
Primary completion
2013-07-01
Completion
2013-12-01
First posted
2013-07-25
Last updated
2020-04-28
Results posted
2015-02-09

Source: ClinicalTrials.gov record NCT01907490. Inclusion in this directory is not an endorsement.